The Brigham and Dana-Farber Board Review in Oncology 2020 (Videos+PDFs)

The Brigham and Dana-Farber Board Review in Oncology 2020

Brigham and Women’s Hospital Board Review

Product Details

Earn CME Credit with this Oncology Review

The Brigham and Dana-Farber Board Review in Oncology is a CME course designed to update knowledge and improve management strategies. Case-based presentations from a distinguished faculty of experts will help enhance patient care while you prep for the board exam by learning to:

• Apply recommended oncology guidelines in clinical practice
• Perform differential diagnosis of complex oncologic disorders
• Identify and apply current therapeutic options for oncologic disorders
• Evaluate and interpret up-to-date literature relevant to oncology
• Illustrate knowledge of pathophysiology as it applies to management of oncology disorders
• Apply knowledge gained to the ABIM certification/recertification oncology examinations

Discover New Guidelines

A clinically based update, this learn-at-your-own-pace CME board review in oncology provides a maximum of 31.75 AMA PRA Category 1 Credits ™ and 31.75 MOC points. Available online or via USB, it provides access to unbiased, evidence-based content and case-based reviews so that you may expand your knowledge and incorporate the latest guidelines into your daily practice.

Accreditation

Oakstone Publishing is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

Oakstone Publishing designates this enduring material for a maximum of 31.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 31.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Date of Original Release: April 15, 2020

Termination Date: April 15, 2023

Learning Objectives

At the conclusion of this activity, the participant will be able to:

• Apply current/recommended Oncology guidelines in clinical practice
• Perform differential diagnosis of complex clinical presentations related to Oncologic disorders
• Identify/apply current therapeutic options for specific Oncologic disorders
• Review and interpret up-to-date literature relevant to clinical practice in Oncology
• Demonstrate knowledge of pathophysiology as it applies to management of Oncology disorders
• Apply knowledge gained to the ABIM Certification/Recertification Medical Oncology examinations

Intended Audience

The activity was planned for fellows/trainees, practicing Oncology specialists (MDs), and other professional affiliates (internists with an interest in Oncology) who are preparing to take ABIM Board Review or Recertification Examinations, or who seek CME activities to improve patient care in the areas of Oncology Medicine.

Topics/Speaker:

• Molecular Genetics of Cancer – Nikhil Wagle, MD

• Advances in Cancer Drug Development – Geoffrey I. Shapiro, MD, PhD

• Infections in Cancer Patients – Lindsey Baden, MD

• Symptom Management in Patients with Cancer – Andrew J. Lawton, MD

• Communication: The Key to Excellence in End-of-Life Care – Rachelle E. Bernacki, MD

• Biology of Hematopoietic Stem Cell Transplantation – Robert J. Soiffer, MD

• Biology of Acute Leukemia and Myelodysplastic Syndromes – Benjamin L. Ebert, MD, PhD

• Acute Leukemias – Daniel J. DeAngelo, MD, PhD

• Myelodysplastic Syndrome – David P. Steensma, MD

• Chronic Myelogenous Leukemia – Marlise R. Luskin, MD

• Myeloproliferative Syndromes – Ann M. Mullally, MD

• Multiple Myeloma – Kenneth C. Anderson, MD

• Waldenstrom Macroglobulemia and Amyloidosis – Jorge Castillo, MD

• Low Grade Lymphomas – Caron A. Jacobson, MD

• High Grade Lymphomas – Eric D. Jacobsen, MD

• Hodgkin’s Lymphoma – Jennifer Crombie, MD

• Diagnosis and Treatment of CLL and Related B Cell Malignancies – Matthew S. Davids, MD

• Head and Neck Cancer – Robert I. Haddad, MD

• Natural History, Screening, Surgery and Small Cell Lung Cancer – Bruce E. Johnson, MD

• Non Small Cell Lung Cancer – Mark Awad, MD, PhD

• Mesothelioma and Thymoma – David M. Jackman, MD

• Thyroid Cancer – Jochen Lorch, MD

• Carcinoid and Pancreatic Neuroendocrine Tumors – Jennifer Ang Chan, MD

• Esophageal and Gastric Cancer – Peter C. Enzinger, MD

• Pancreatic and Hepatobiliary Cancer – Brian M. Wolpin, MD

• Anal Cancers – Robert J. Mayer, MD

• Colorectal Cancers – Robert J. Mayer, MD

• Gastrointestinal Cancer: Genetic Syndromes – Matthew Yurgelun, MD

• Germ Cell Tumor: Maximizing Cure While Minimizing the Burden of Therapy – Mark M. Pomerantz, MD

• Renal and Bladder Cancer – Guru P. Sonpavde, MBBS

• Prostate Cancer Part I: Overview and Management of Localized Disease – Atish Choudhury, MD, PhD

• Prostate Cancer Part II: Management of Disseminated Prostate Cancer – Atish Choudhury, MD, PhD

• Melanoma – F. Stephen Hodi, MD

• Sarcomas and Gastrointestinal Stromal Tumors (GIST) – George D. Demetri, MD

• Ovarian Cancer – Ursula A. Matulonis, MD

• Cervical and Endometrial Cancer – Panagiotis A. Konstantinopoulos, MD, PhD

• Neuro-oncology – David A. Reardon, MD

• Breast Cancer: Risk Factors, Genetics, Screening, and Prevention – Judy E. Garber, MD, MPH

• Multimodality Therapy for Early Stage Breast Cancer: Part 1 – Surgery and Radiation – Harold J. Burstein, MD, PhD

• Multimodality Therapy for Early Stage Breast Cancer: Part 2 – Systemic Therapy – Harold J. Burstein, MD, PhD

• Management of Metastatic Breast Cancer – Erica Mayer, MD, MPH

• Breast Cancer Survivorship – Ann H. Partridge, MD, MPH